López-Cerdá S, Molinaro G, ParejaTello R, Correia A, Künig S, Steinberger P, et al.. Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid?Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy. ACS Applied Materials & Interfaces [Internet]. 2024;16(15):18643 - 18657. https://pubs.acs.org/doi/10.1021/acsami.4c02363

Leppänen V-M, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, et al.. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085

Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, et al.. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010;107(6):2425 - 30. http://view.ncbi.nlm.nih.gov/pubmed/20145116

Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841

Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, et al.. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J [Internet]. 2001;20(6):1223 - 31. http://view.ncbi.nlm.nih.gov/pubmed/11250889

Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, et al.. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. In Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Miami Beach, Florida; 2001.